| Autor: |
Arzuaga, Alazne, Maynar, Javier, Gascón, Alicia R., Isla, Arantxazu, Corral, Esther, Fonseca, Fernando, Sánchez-Izquierdo, José Ángel, Rello, Jordi, Canut, Andrés, Pedraz, José Luis |
| Zdroj: |
Journal of Clinical Pharmacology; Feb2005, Vol. 45 Issue 2, p168-176, 9p |
| Abstrakt: |
The pharmacokinetics of piperacillin/tazobactam (4 g/0.5 g every 6 or 8 hours, by 20-minute intravenous infusion) were studied in 14 patients with acute renal failure whounderwent continuous venovenous hemofiltration with AN69 membranes. Patients were grouped according to severity (CLCR≤10 mL/min, 10 < CLCR≤50 mL/min, and CLCR > 50mL/min). A noncompartmental analysis was performed. The sieving coefficient (0.78 ±0.28) was similar to the unbound fraction (0.65±0.24) for tazobactam, but it was significantly different (0.34±0.25) from the unbound fraction (0.78 ± 0.14) for piperacillin. Extracorporeal clearance was 37.0%±28.8%, 12.7%±12.6%, and 2.8%±3.2% for piperacillin in each group and 62.5%±44.9%, 35.4%±17.0%, and 13.1%± 8.0% for tazobactam. No patients presented tazobactam accumulation. In patients with CLCR < 50mL/min, tss(%) > MIC90 values were100% for a panel of 19 pathogens, but in thosewith CLCR > 50mL/min, tss(%) > MIC90 indexes were 55.5% and 16.6% for pathogens with MIC90 values of 32 and 64. The extracorporeal clearance of piperacillin/tazobactam is clinically significant in patients with CLCR > 50mL/min, in which the risk of underdosing and clinical failure is important and extra doses are required. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text